LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Strona główna・Stock List・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Closed

SectorHealthcare

23.65 -0.46

Buy Sell

Overview

Share price change

24h

Current

Min

23.4

Max

23.98

Key metrics
By Trading Economics
Income	-7.3M -68M
Sales	23M 68M
Profit margin	-99.318
Employees	298
EBITDA	42M -15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+77.28% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	391M 2.1B
Previous open	24.11
Previous close	23.65

News Sentiment

By Acuity

50%

171 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

9.91 / 14.15 Support & Resistance

Syndax Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 mar 2026, 22:51 UTC

Earnings

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar 2026, 21:40 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar 2026, 20:31 UTC

Earnings

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar 2026, 23:49 UTC

Market Talk

Major News Events

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar 2026, 22:36 UTC

Earnings

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar 2026, 22:24 UTC

Earnings

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar 2026, 22:23 UTC

Earnings

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar 2026, 22:23 UTC

Earnings

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar 2026, 21:58 UTC

Earnings

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar 2026, 21:55 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

18 mar 2026, 21:55 UTC

Market Talk

Earnings

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar 2026, 21:00 UTC

Major News Events

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar 2026, 20:58 UTC

Earnings

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar 2026, 20:41 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:29 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:25 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:17 UTC

Earnings

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar 2026, 20:09 UTC

Earnings

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar 2026, 20:07 UTC

Earnings

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar 2026, 20:06 UTC

Earnings

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar 2026, 20:04 UTC

Earnings

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar 2026, 20:04 UTC

Earnings

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar 2026, 20:04 UTC

Earnings

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar 2026, 20:03 UTC

Earnings

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

77.28% upside

12 Months Forecast

Average 42.14 USD 77.28%

High 57 USD

Low 28 USD

Based on 8 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Syndax Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

9.91 / 14.15Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

171 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.